Recombinant factor VIIa improves XXXX caused by @entity1578 .

@entity1 @entity548 @entity879 @entity1003 @entity3459 @entity1578 @entity715
OBJECTIVE: @entity1003 is an important cause of morbidity and mortality in @entity1 with @entity1578 . The benefit of traditional therapies to @entity3459 is often limited and short-lived. Our aim is to identify indications for rFVIIa use and the outcome of treatment in @entity1 with @entity1578 . METHODS: A retrospective review from July 2000 to December 2001 was performed to identify consecutive @entity1 with @entity879 who received rFVIIa. Prothrombin times (PT) before and after therapy were compared by paired t test. RESULTS: Fifteen @entity1 were treated with rFVIIa for @entity1003 caused by @entity1578 . All were receiving fresh frozen plasma (mean infusion rate, 39.7 mL/kg/day) when rFVIIa therapy was started. The mean PT before rFVIIa was 32.0 +/- 7.0 seconds. One hour after infusion, the PT normalized to 13.7 +/- 2.4 seconds (P < 0.0001) and remained significantly reduced at 6 hours (19.8 +/- 5.3 seconds; P < 0.0001). A sustained improvement was maintained during the subsequent 3 days. Five of seven @entity1 with @entity548 complications improved clinically after rFVIIa treatment. Two of the @entity548 @entity1 also benefited from improved fluid balance as fresh frozen plasma support was reduced. No @entity715 events were attributed to rFVIIa therapy. CONCLUSIONS: In @entity1 with @entity1578 , rFVIIa therapy quickly normalizes the PT and maintains improved hemostasis, even when @entity1003 has been refractory to fresh frozen plasma. Therapy subjectively reduces clinical @entity548 and can improve fluid balance, without complications.
